Form 4: Nurix Therapeutics Director, David L. Lacey, Acquires 25,000 Stock Options
SEC Form 4 Filing
David L. Lacey, a director of Nurix Therapeutics, acquired 25,000 stock options on May 20, 2024, exercisable at $16.19.
Summary
- On May 20, 2024, David L. Lacey, a director of Nurix Therapeutics, acquired 25,000 stock options.
- The exercise price of these options is $16.19.
- The options vest 100% on the earlier of the next annual meeting of the Issuer's stockholders or May 20, 2025, subject to continued service.
- The options expire on May 19, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of stock options, which can be interpreted as a sign of confidence, but it doesn't inherently indicate a strong positive or negative outlook.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's investment in the company's future.
Stakeholder Impact
- Shareholders may view the director's acquisition of stock options as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of transaction: David L. Lacey acquired 25,000 stock options. |
| 05/20/2025 | Vesting date: Options vest 100% on the earlier of the next annual meeting of the Issuer's stockholders or this date, subject to continued service. |
| 05/19/2034 | Expiration date: Stock options expire on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.